Want to see HK:2252 full AI Analyst Report?
Top Page
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
(2252)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$20.50
▼(-6.82% Downside)
Action:Upgraded
Date:10/18/26
The score is held down primarily by weak financial quality—continued losses, negative cash flow, and negative returns—despite strong recent revenue growth and improving leverage. Technical indicators also lean bearish with price below key moving averages and negative MACD. Valuation is constrained by a negative P/E and no dividend yield support.
Positive Factors
Revenue Acceleration
The sharp acceleration in revenue indicates improving commercial traction for the company’s medical robotics business. If sustained, stronger system adoption can expand the installed base and create additional recurring demand for instruments, consumables, and services over the next several quarters.
Negative Factors
Persistent Unprofitability
The company remains materially unprofitable, so revenue growth has not yet translated into sustainable earnings. A large net loss can limit internally funded investment, require continued external support, and make the durability of the business model dependent on achieving substantial operating leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Acceleration
The sharp acceleration in revenue indicates improving commercial traction for the company’s medical robotics business. If sustained, stronger system adoption can expand the installed base and create additional recurring demand for instruments, consumables, and services over the next several quarters.
Read all positive factors
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$21.97B
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)1.64
Revenue Growth114.97%
EPS Growth63.21%
CountryHK
Employees464
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.24
Shares Outstanding1,030,720,600
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.43
Price to Book (P/B)54.27
Price to Sales (P/S)40.46
P/FCF Ratio-574.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)HK$1.22B
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai MicroPort MedBot (Group) Co., Ltd. focuses on the comprehensive research, development, design, production, and distribution of surgical robotic systems, catering to markets in China and Europe. Their innovative product range features Toum...
How the Company Makes Money
MicroPort MedBot generates revenue primarily by selling its medical robotic systems and related products/services to healthcare providers (e.g., hospitals and clinical centers), typically through (i) system/device sales and (ii) recurring revenue ...
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
45
Neutral
Cash Flow
33
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 551.07M | 257.25M | 104.59M | 21.60M | 2.15M |
| Gross Profit | 266.62M | 86.22M | 14.69M | 6.56M | 919.00K |
| EBITDA | -62.02M | -356.54M | -893.36M | -996.26M | -543.84M |
| Net Income | -249.66M | -642.41M | -1.01B | -1.14B | -582.92M |
Balance Sheet | |||||
| Total Assets | 1.34B | 1.28B | 1.43B | 1.93B | 2.79B |
| Cash, Cash Equivalents and Short-Term Investments | 640.42M | 612.23M | 507.71M | 747.96M | 1.94B |
| Total Debt | 426.37M | 691.33M | 560.42M | 219.95M | 204.68M |
| Total Liabilities | 935.07M | 1.02B | 926.15M | 522.25M | 401.73M |
| Stockholders Equity | 410.85M | 278.20M | 519.48M | 1.42B | 2.39B |
Cash Flow | |||||
| Free Cash Flow | -38.83M | -340.21M | -634.30M | -1.09B | -674.47M |
| Operating Cash Flow | -36.30M | -298.12M | -567.84M | -898.48M | -540.49M |
| Investing Cash Flow | 2.55M | -47.60M | -58.38M | -267.82M | -396.57M |
| Financing Cash Flow | 66.32M | 449.96M | 385.68M | -27.95M | 1.39B |
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Technical Analysis
Negative
22.00
Price Trends
21.46
Negative
22.36
Negative
24.89
Negative
Market Momentum
-0.08
Negative
40.02
Neutral
44.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2252, the sentiment is Negative. The current price of 22 is above the 20-day moving average (MA) of 21.18, above the 50-day MA of 21.46, and below the 200-day MA of 24.89, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 40.02 is Neutral, neither overbought nor oversold. The STOCH value of 44.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2252.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$5.05B | 11.38 | 13.24% | 2.59% | 16.15% | 31.89% | |
67 Neutral | HK$4.71B | 21.31 | 10.38% | 1.74% | 3.83% | -27.04% | |
59 Neutral | HK$2.82B | 27.71 | 4.08% | ― | 94.80% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$1.63B | -0.86 | -6.69% | ― | ― | ― | |
46 Neutral | HK$11.65B | 31.23 | 6.07% | 0.06% | -3.62% | ― | |
42 Neutral | HK$21.97B | -74.88 | -52.78% | ― | 114.97% | 63.21% |
* Healthcare Sector Average
HK:2252
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
21.18
-6.24
-22.76%
HK:0853
MicroPort Scientific
6.08
-6.03
-49.83%
HK:1789
AK Medical Holdings Ltd.
4.56
-1.18
-20.52%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.28
-4.67
-78.49%
HK:2172
MicroPort NeuroTech Limited
8.06
-3.70
-31.47%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
6.70
0.02
0.30%
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Corporate Events
MicroPort MedBot delays 2026 interim results, trading suspended amid lease review
Sep 1, 2026
Shanghai MicroPort MedBot has announced a delay in publishing its interim results for the six months ended 30 June 2026, citing the need for additional time to confirm the relationship between a lease counterparty and the group. As a result, the c...
MicroPort MedBot Forms ESG Committee to Bolster Sustainable Governance
Aug 27, 2026
Shanghai MicroPort MedBot (Group) Co., Ltd., a Hong Kong-listed PRC medical technology group specializing in surgical robotics, has a diversified board structure with executive, non-executive and independent non-executive directors providing overs...
Shanghai MicroPort MedBot Details Board and Committee Structure
Aug 27, 2026
Shanghai MicroPort MedBot (Group) Co., Ltd. has announced the current composition of its board of directors, which includes one executive director, several non-executive directors, and independent non-executive directors. The disclosure clarifies ...
Shanghai MicroPort MedBot Reshapes Board With New Non-Executive Director Nominations
Aug 27, 2026
Shanghai MicroPort MedBot (Group) Co., Ltd. announced board changes, with executive director Yu Liu resigning immediately and non-executive director Min Liang stepping down after the forthcoming extraordinary general meeting to devote more time to...
Shanghai MicroPort MedBot Delays Board Meeting to Finalize Interim Results
Aug 27, 2026
Shanghai MicroPort MedBot (Group) Co., Ltd. has postponed a scheduled board meeting originally set for 27 August 2026, which was convened to review and approve the group’s interim results for the six months ended 30 June 2026 and to consider...
MicroPort MedBot Subsidiary Ends Connected Finance Lease to Cut Costs
Aug 27, 2026
Shanghai MicroPort MedBot’s subsidiary Navibot Suzhou has entered into a termination agreement with related party Tianniuyan covering a previous finance lease for technology prototypes, paying a settlement of RMB20.92 million to obtain full ...
MicroPort MedBot Sets August Board Meeting to Review Interim Results and Dividend
Aug 17, 2026
Shanghai MicroPort MedBot (Group) Co., Ltd. has scheduled a board meeting for 27 August 2026 to review and approve the group’s interim financial results for the six months ended 30 June 2026 and to authorize their public release. The board w...
MicroPort MedBot Forecasts First Semi-Annual Profit on Surging Robot Sales
Jul 22, 2026
Shanghai MicroPort MedBot announced it expects to swing from a net loss to a net profit of about RMB28 million to RMB40 million for the six months ended 30 June 2026, compared with a RMB115 million loss a year earlier. This would mark the company&...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.